Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-angiogenic therapies for the treatment of angiosarcoma: aclinical update

Anti-angiogenic therapies for the treatment of angiosarcoma: aclinical update Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Anti-angiogenic therapies for the treatment of angiosarcoma: aclinical update

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/anti-angiogenic-therapies-for-the-treatment-of-angiosarcoma-aclinical-XDB0m0WLBe
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0365-x
Publisher site
See Article on Publisher Site

Abstract

Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents. A number of small prospective studies have reported angiosarcoma response to vascular-targeted agents, including agents that target vascular endothelial growth factor. To date, the response to these agents has been disappointing, and similar to the response observed in other soft tissue sarcoma subtypes. This short review will summarise the recent data in this field.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 7, 2017

References

  • Angiosarcoma
    Young, RJ; Brown, NJ; Reed, MW; Hughes, D; Woll, PJ
  • The microtubule-affecting drug paclitaxel has antiangiogenic activity
    Belotti, D; Vergani, V; Drudis, T; Borsotti, P; Pitelli, MR; Viale, G
  • Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study
    Penel, N; Bui, BN; Bay, JO; Cupissol, D; Ray-Coquard, I; Piperno-Neumann, S
  • First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
    Young, RJ; Natukunda, A; Litière, S; Woll, PJ; Wardelmann, E; Graaf, WT
  • An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
    Agulnik, M; Yarber, JL; Okuno, SH; Mehren, M; Jovanovic, BD; Brockstein, BE
  • Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial
    Ray-Coquard, IL; Domont, J; Tresch-Bruneel, E; Bompas, E; Cassier, PA; Mir, O
  • Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Maki, RG; D’Adamo, DR; Keohan, ML; Saulle, M; Schuetze, SM; Undevia, SD
  • Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
    Ray-Coquard, I; Italiano, A; Bompas, E; Cesne, A; Robin, YM; Chevreau, C
  • Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)
    Sleijfer, S; Ray-Coquard, I; Papai, Z; Cesne, A; Scurr, M; Schöffski, P
  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
    Graaf, WT; Blay, JY; Chawla, SP; Kim, DW; Bui-Nguyen, B; Casali, PG
  • Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
    Kollár, A; Jones, RL; Stacchiotti, S; Gelderblom, H; Guida, M; Grignani, G
  • AXI-STS: A UK NCRI Sarcoma Clinical Studies Group phase II trial of the VEGFR inhibitor axitinib in advanced soft tissue sarcoma (STS)
    Penella, W; Piers, G; Ian, J; Sandra, S; Jeremy, W; Michael, L
  • Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
    Mir, O; Brodowicz, T; Italiano, A; Wallet, J; Blay, JY; Bertucci, F
  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    Tap, WD; Jones, RL; Tine, BA; Chmielowski, B; Elias, AD; Adkins, D
  • TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets
    Jonker, L
  • A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
    Rosen, LS; Hurwitz, HI; Wong, MK; Goldman, J; Mendelson, DS; Figg, WD
  • A phase 1B/phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS)
    Attia, S; Sankhala, KK; Riedel, RF; Robinson, SI; Conry, RM; Boland, PM
  • Thalidomide—a notorious sedative to a wonder anticancer drug
    Zhou, S; Wang, F; Hsieh, TC; Wu, JM; Wu, E
  • Complete response from thalidomide in angiosarcoma after treatment of breast cancer
    Raina, V; Sengar, M; Shukla, NK; Deo, SS; Mohanty, BK; Sharma, D
  • Thalidomide combined with neoadjuvant chemotherapy in angiosarcoma of the breast with complete pathologic response: case report and review of literature
    Alvarado-Miranda, A; Bacon-Fonseca, L; Ulises Lara-Medina, F; Maldonado-Martínez, H; Arce-Salinas, C
  • Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
    Penel, N; Adenis, A; Bocci, G
  • Review: metronomic chemotherapy for advanced cutaneous angiosarcoma
    Wong, H; Yau, T
  • Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
    Mir, O; Domont, J; Cioffi, A; Bonvalot, S; Boulet, B; Pechoux, C
  • Infantile haemangioma
    Léauté-Labrèze, C; Harper, JI; Hoeger, PH
  • Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma
    Stiles, JM; Amaya, C; Rains, S; Diaz, D; Pham, R; Battiste, J
  • Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study
    Pasquier, E; André, N; Street, J; Chougule, A; Rekhi, B; Ghosh, J
  • KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors
    Antonescu, CR; Yoshida, A; Guo, T; Chang, NE; Zhang, L; Agaram, NP
  • Recurrent PTPRB and PLCG1 mutations in angiosarcoma
    Behjati, S; Tarpey, PS; Sheldon, H; Martincorena, I; Loo, P; Gundem, G
  • Angiogenic growth factor expression in benign and malignant vascular tumours
    Young, RJ; Fernando, M; Hughes, D; Brown, NJ; Woll, PJ
  • Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas
    Itakura, E; Yamamoto, H; Oda, Y; Tsuneyoshi, M